AI brief of an SEC Form 8-K · CAPRICOR THERAPEUTICS, INC. (CAPR)

Capricor Q2 net loss widens to $40.7 million as Deramiocel FDA review continues

Negative Impact 4 of 5 earnings Written later

Capricor reported a second-quarter 2026 net loss of $40.7 million, or $0.70 per share, up from $25.9 million, or $0.57 per share, a year earlier, with no revenue recognized. The company said its FDA Advisory Committee voted 3 in favor and 9 against on cardiomyopathy efficacy for Deramiocel, and it is still working with the FDA on the Biologics License Application.

Key points

Q2 2026 net loss of $40.7 million, or $0.70 per share, versus $25.9 million, or $0.57 per share, in Q2 2025
Cash, cash equivalents and marketable securities of $237.9 million at June 30, 2026, down from $318.1 million at December 31, 2025
On July 29, 2026, the FDA Cellular, Tissue and Gene Therapies Advisory Committee voted 3 in favor and 9 against; the vote is advisory and non-binding
NS Pharma preliminary injunction motion withdrawn; the company estimates arbitration will begin this fall

The filing

CompanyCAPRICOR THERAPEUTICS, INC. (CAPR)

Form8-K, current report

Filed with the SECAug 13, 2026, 4:07 PM ET

Accession number0001104659-26-095908

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.